Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Myasthenia Gravis

• A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
• A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
• Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
• Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
• Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
• Zilucoplan for Severe gMG Exacerbations
• Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
• A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese
• Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
• Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
• GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
• Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
• Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
• Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
• The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
• Universal Chimeric Antigen Receptor T-Cell UCAR T-cell Therapy Targeting CD19/B Cell Maturation Antigen CD19/BCMA in Patients With r/r Neurological Autoimmune Diseases
• The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis
• Blinatumomab for Treatment of Refractory Myasthenia Gravis
• Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis
• Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
• An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
• Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
• A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
• Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
• A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
• A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
• Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis
• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
• An Exploratory Clinical Study of GC012F Injection for Refractory gMG
• Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
• Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
• Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
• A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
• Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
• Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
• Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
• Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
• Study of Telitacicept in Generalized Myasthenia Gravis
• Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
• A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
• Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
• An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
• Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
• Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
• Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
• A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
• Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
• Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
• A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis
• Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
• Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis
• A Study to Evaluate Thefficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized MG Patients
• Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
• Oxaloacetate in Myasthenia Gravis
• A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
• Subcutaneous Immunoglobulin for Myasthenia Gravis
• A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
• Myasthenia Gravis Inebilizumab Trial
• Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
• A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
• Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
• A Study of TAK-079 in People With Generalized Myasthenia Gravis
• Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
• Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
• A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
• Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis
• An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
• A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
• A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
• A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
• Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
• Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis
• Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
• Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
• Trial of Orencia in Patients With Myasthenia Gravis
• Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
• A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
• A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
• A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
• Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
• Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
• BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
• Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
• Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
• Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
• The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
• A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
• A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
• Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
• Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
• Efficacy of Prednisone In the Treatment of Ocular Myasthenia
• Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
• Efficacy of Methotrexate in Myasthenia Gravis
• Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
• Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
• Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
• A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis
• A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
• Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
• A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
• An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
• FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
• Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
• Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
• Mycophenolate Mofetil in Myasthenia Gravis
• Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis